Isomorphic Labs, the AI drug design company founded by Sir Demis Hassabis, has raised $5 billion in Series C funding — a round that industry outlet BioSpace reports breaks the record for the largest venture fundraising round in biotech. The announcement was published on the company's website on November 17, with Bloomberg confirming that the round was co-led by Greenoaks and Sequoia Capital.

The mega-round is the biggest AI industry funding story of the week, and it signals that investors are still willing to place enormous bets on AI-first approaches to science despite broader questions about AI-sector valuations.

Who Is Backing the Round

According to Isomorphic Labs' announcement, the $5 billion Series C was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet, the company's original parent. Every existing investor also participated, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.

The round comes just months after the company announced its $2.1 billion Series B in May 2026, an unusually fast turnaround between mega-rounds that reflects both the capital intensity of AI drug design and investor conviction in the platform's progress.

Where the $5 Billion Will Go

Isomorphic Labs is focused on designing and developing new medicines with AI. In its announcement, the company said the funding will accelerate the scaling of its proprietary drug design engine — known as IsoDDE, the Isomorphic Labs Drug Design Engine — and its pipeline of therapeutic candidates designed with AI.

Critically, the company says its lead internal programs are now advancing towards the clinic. TechCrunch reported that the funding is aimed at taking drug candidates to clinical trials, the costliest and most demanding phase of drug development and the key proof point for whether AI-designed medicines can succeed where traditional pipelines have struggled.

The company's stated ambition remains sweeping. "Even if we could accurately predict the properties of a billion molecules, we would still have explored only a tiny fraction of the possible design space," Max Jaderberg, the company's president, explains on Isomorphic's website. "We're going further than prediction, with models that can learn how to navigate that space to find a universe of possibilities beyond human intuition."

Hassabis Bets Fully on Isomorphic

The record round is also a statement about its founder. CNBC noted that the raise comes months after Hassabis left his role as Google DeepMind's CEO, leaving him free to devote himself fully to Isomorphic Labs as founder and chief executive.

Hassabis, who won the 2024 Nobel Prize in Chemistry for his work on protein structure prediction, has framed Isomorphic's mission as the most important application of AI anywhere. "I believe there is no more important application for AI than helping to improve human health," Hassabis says in materials on the company's website. "But success isn't just coming up with one medicine. We're building towards a systematic way to discover and design medicines across many different diseases, and ultimately change what it is possible to treat."

The company was built on the lineage of AlphaFold, DeepMind's breakthrough protein structure prediction system, and has since expanded into a broader drug design platform that combines predictive and generative AI models with experimental biology. Its commercial strategy includes research partnerships with major pharmaceutical companies, including a collaboration with Johnson & Johnson announced in January 2026.

What the Record Round Means for AI Drug Discovery

The $5 billion Series C resets the benchmark for capital flowing into AI-native biotech. For Isomorphic, the money arrives at the moment its internally designed candidates make the leap from computational predictions to human trials — the milestone that will ultimately test whether AI drug design can compress the timelines and costs that have made pharmaceutical R&D notoriously slow and expensive.

For the wider field, the message is that top-tier investors are separating AI science platforms from the broader AI market's volatility. With Alphabet continuing to invest alongside new money from Sequoia, Greenoaks, and a16z, Isomorphic Labs now has one of the best-capitalized balance sheets in biotech to prove that AI can design medicines, not just predict molecules.

Inside the Drug Design Engine

The technology underpinning that bet is IsoDDE, the company's proprietary drug design engine. According to Isomorphic's own description, its predictive and generative models help researchers probe biology's complexity, navigate vast chemical space, and solve problems that have long confounded medicinal chemistry — moving beyond AI as a structure-prediction tool toward AI as an active designer of candidate molecules.

That progression has been building for years. The company emerged from the research lineage of AlphaFold, the protein structure prediction system whose success demonstrated that neural networks could solve problems biologists had written off as intractable, and it has since layered generative design capabilities on top of that predictive foundation. Alongside internal programs, the company has pursued partnerships with large pharmaceutical firms — including a research collaboration with Johnson & Johnson announced in January 2026 — that pair Isomorphic's models with industry-scale chemistry and clinical expertise.

The UK angle is also notable: the UK Sovereign AI Fund's participation, alongside Temasek and strategic arms of Alphabet, gives the round a geopolitical dimension, aligning one of Britain's most prominent AI science companies with sovereign capital as governments compete to anchor frontier AI research within their borders.

Whether IsoDDE-designed candidates clear the clinical bar will take years to determine. But with $5 billion in new capital, an advancing internal pipeline, and its founder now fully at the helm, Isomorphic Labs has assembled the resources to run that experiment at unprecedented scale.

Stay Ahead of AI

Follow the funding stories shaping the AI industry: Read more AI news →